Dermatologie - MedQual

Références1. Mulder WM, Meinardi MM, Bruynzeel DP. Huidreacties door geneesmiddelen. Ned Tijdschr Geneeskd2004;148:415-20.2. Gielen K, Goossens A. Contactallergische reacties bij medisch personeel door geneesmiddelen. TijdschrGeneeskd 2004;60:1776-84.3. Hodkinson B, Nay R & Wilson J: A systematic review of topical skin care in aged care facilities. J ClinNurs2007;16:129-36.4. NICE. Frequency of application of topical corticosteroids for atopic eczema. Technology Appraisal 81 -August 2004. www.nice.org.uk5. Prodigy Guidance. Dermatitis – contact. April 2005. http://cks.library.nhs.uk/6. Saary J, Qureshi R, Palda V et al. A systematic review of contact dermatitis treatment and prevention. JAm Acad Dermatol 2005;53:845-55.7. Anonymous. Topical steroids for atopic dermatitis in primary care. Drug Ther Bull 2003;41:5-8.8. Anonymous. Atopic eczema in primary care. MeReC Bulletin NHS 2004;14:1-4.http://www.npc.co.uk/MeReC_Bulletins/2003Volumes/Vol14no1.pdf9. Williams H, Bigby M, Diepgen T et al. Evidence Based Dermatology. BMJ Books. April 2003.10. Dermatocorticosteroïden. Farmacotherapeutisch Kompas 2007. http://www.fk.cvz.nl/11. Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectiveness of once-daily versus more frequent useof same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.Health Technology Assessment 2004;8(47).12. Anonymous. Tacrolimus dermique: trop d’inconnues pour utiliser cet immunosuppresseur par voiecutanée. La Revue Prescrire 2003;23:805-9.13. Ashcroft D, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimusin the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516-22.14. Garside R, Stein K, Castelnuovo E et al. The effectiveness and cost-effectiveness of pimecrolimus andtacrolimus for topic eczema: a systematic review and economic evaluation. Health TechnologyAssessment 2005;9(29).15. Anonymous. Pimécrolimus ou tacrolimus dermique et cancer. Revue Prescrire 2005;264:592.16. EMEA. Safety review of tacrolimus ointment and pimecrolimus cream. (CHMP/102937/2006, Rev.)www.emea.europa.eu17. Anonymous. Pimecrolimus. Aust Prescr 2003;26:149-50.http://www.australianprescriber.com/magazine/26/6/146/51/18. NGC. Tacrolimus and pimecrolimus for atopic eczema. NGC October 6, 2005 www.guideline.gov19. NICE. Tacrolimus and pimecrolimus for atopic eczema. Technology Appraisal 82 - august 2004.20. Manriquez JJ, Uribe P. Seborrhoeic dermatitis. BMJ Clinical evidence [online] 2007 [cited june].21. Manriquez JJ, Uribe P. Seborrhoeic dermatitis. BMJ Clinical evidence [online] 2007 [cited june].22. Prodigy Guidance. Seborrhoeic dermatitis. November 2004. http://cks.library.nhs.uk/23. Van Zuuren EJ, Graber MA, Hollis S et al. Interventions for rosacea. The Cochrane Database ofSystematic Reviews 2005, Issue 3. Art. No.: CD003262. DOI: 10.1002/14651858.CD003262.pub3.24. Van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J AmAcad Dermatol 2007:56:107-15.25. Anonymous. De behandeling van rosacea. Geneesmiddelenbulletin 1998;32:101-5.http://www.geneesmiddelenbulletin.nl/26. Prodigy Guidance. Rosacea. July 2005. http://www.cks.library.nhs.uk/27. Prodigy Guidance Warts (including verrucas); january 2007. http://www.cks.library.nhs.uk/28. Luk NM, Tang YM. Warts (non-genital). BMJ Clinical evidence [online] 2007 [cited june].29. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract2003;53:480-7.30. Koning S, Verhagen AP, van Suijlekom-Smit LWA et al. Interventions for impetigo. The CochraneDatabase of Systematic Reviews 2003, Issue 2. Art. No.: CD003261.pub2. DOI:10.1002/14651858.CD003261.pub2.31. HPA Management of infection guidance for primary care for consultation & local adaptation. HealthProtection Agency. www.hpa.org.uk geraadpleegd op 10/04/06.32. Middelen bij wondbehandeling en desinfectie van de huid. Farmacotherapeutisch Kompas 2007.http://www.fk.cvz.nl/33. Bacteriële huidinfecties. Farmacotherapeutisch Kompas 2007. http://www.fk.cvz.nl/Dermatologie 437